ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
In a heated race with some of pharma’s biggest players, Roche’s Genentech is looking to drive a lead bispecific antibody program through the clinic against stubborn blood cancers. As the field watches closely, Roche is now trotting out data it thinks could earn its drug a first shot at the market.
Roche’s mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60% complete response rate, according to data from nearly 100 patients with third-line-or-later follicular lymphoma in an open-label, single-arm Phase I/II study dubbed GO29781 presented Saturday at #ASH21.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.